Literature DB >> 28210792

[Paraneoplastic serous retinopathies: hormones, mediators, and inhibitors].

R S Grajewski1, L M Heindl2.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28210792     DOI： 10.1007/s00347-017-0459-1

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN： 0941-293X            Impact factor:   1.059


× No keyword cloud information.
  10 in total

1.  Bilateral subfoveal neurosensory retinal detachment associated with MEK inhibitor use for metastatic cancer.

Authors:  Tara A McCannel; Bartosz Chmielowski; Richard S Finn; Jonathan Goldman; Antoni Ribas; Zev A Wainberg; Colin A McCannel
Journal:  JAMA Ophthalmol       Date:  2014-08       Impact factor: 7.389

2.  Acute exudative polymorphous paraneoplastic vitelliform maculopathy in a patient with carcinoma, not melanoma.

Authors:  Lili Grunwald; Brad E Kligman; Carol L Shields
Journal:  Arch Ophthalmol       Date:  2011-08

Review 3.  MEK inhibitors: a new class of chemotherapeutic agents with ocular toxicity.

Authors:  K E Duncan; L Y Chang; M Patronas
Journal:  Eye (Lond)       Date:  2015-06-05       Impact factor: 3.775

4.  Ocular diseases in metastatic cutaneous melanoma: review of 108 consecutive patients in two German tertiary centers.

Authors:  Rafael S Grajewski; Beatrice Schuler-Thurner; Cornelia Mauch; Nicole Kreuzberg; Konrad R Koch; Antonio Bergua; Claus Cursiefen; Ludwig M Heindl
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-01-22       Impact factor: 3.117

5.  Malignant melanoma with ectopic production of adrenocorticotropic hormone. Palliative treatment with inhibitors of adrenal steroid biosynthesis.

Authors:  R M Carey; D N Orth; W H Hartmann
Journal:  J Clin Endocrinol Metab       Date:  1973-03       Impact factor: 5.958

6.  [Development of serous retinopathy during therapy of a metastatic cutaneous melanoma].

Authors:  I Lüdeke; P Terheyden; S Grisanti; M Lüke
Journal:  Ophthalmologe       Date:  2016-10       Impact factor: 1.059

Review 7.  Molecular basis of the inner blood-retinal barrier and its breakdown in diabetic macular edema and other pathological conditions.

Authors:  Ingeborg Klaassen; Cornelis J F Van Noorden; Reinier O Schlingemann
Journal:  Prog Retin Eye Res       Date:  2013-02-13       Impact factor: 21.198

8.  Subretinal Fluid Associated With MEK Inhibitor Use in the Treatment of Systemic Cancer.

Authors:  Marissa L Weber; Michelle C Liang; Keith T Flaherty; Jeffrey S Heier
Journal:  JAMA Ophthalmol       Date:  2016-08-01       Impact factor: 7.389

9.  Acute exudative polymorphous vitelliform maculopathy in a young man: a case report.

Authors:  Kunjal K Modi; Daniel B Roth; Stuart N Green
Journal:  Retin Cases Brief Rep       Date:  2014

10.  Central serous chorioretinopathy with subretinal deposition of fibrin-like material and its prompt response to ranibizumab injections.

Authors:  Chrysanthos Symeonidis; Konstantinos Kaprinis; Kyriakos Manthos; Sofia Androudi; Konstantinos Anastassilakis; Stavros A Dimitrakos
Journal:  Case Rep Ophthalmol       Date:  2011-02-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.